GB202005114D0 - Crystalline Forms of a Pharmaceutical Compound - Google Patents

Crystalline Forms of a Pharmaceutical Compound

Info

Publication number
GB202005114D0
GB202005114D0 GBGB2005114.0A GB202005114A GB202005114D0 GB 202005114 D0 GB202005114 D0 GB 202005114D0 GB 202005114 A GB202005114 A GB 202005114A GB 202005114 D0 GB202005114 D0 GB 202005114D0
Authority
GB
United Kingdom
Prior art keywords
crystalline forms
pharmaceutical compound
pharmaceutical
compound
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2005114.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sareum Ltd
Original Assignee
Sareum Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sareum Ltd filed Critical Sareum Ltd
Priority to GBGB2005114.0A priority Critical patent/GB202005114D0/en
Publication of GB202005114D0 publication Critical patent/GB202005114D0/en
Priority to KR1020227038120A priority patent/KR20220164751A/ko
Priority to IL296989A priority patent/IL296989A/en
Priority to MX2022011593A priority patent/MX2022011593A/es
Priority to PCT/EP2021/058864 priority patent/WO2021204762A1/en
Priority to AU2021253128A priority patent/AU2021253128A1/en
Priority to EP21717041.4A priority patent/EP4132649A1/en
Priority to CN202180025999.3A priority patent/CN115515683B/zh
Priority to CA3167172A priority patent/CA3167172A1/en
Priority to US17/905,183 priority patent/US12545652B2/en
Priority to JP2022559959A priority patent/JP7660135B2/ja
Priority to BR112022016359A priority patent/BR112022016359A2/pt
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GBGB2005114.0A 2020-04-07 2020-04-07 Crystalline Forms of a Pharmaceutical Compound Ceased GB202005114D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB2005114.0A GB202005114D0 (en) 2020-04-07 2020-04-07 Crystalline Forms of a Pharmaceutical Compound
BR112022016359A BR112022016359A2 (pt) 2020-04-07 2021-04-06 Formas cristalinas de um composto farmacêutico
PCT/EP2021/058864 WO2021204762A1 (en) 2020-04-07 2021-04-06 Crystalline forms of a tyk2 inhibitor
IL296989A IL296989A (en) 2020-04-07 2021-04-06 Crystalline forms of a tyk2 inhibitor
MX2022011593A MX2022011593A (es) 2020-04-07 2021-04-06 Formas cristalinas de un compuesto farmaceutico.
KR1020227038120A KR20220164751A (ko) 2020-04-07 2021-04-06 Tyk2 억제제의 결정질 형태
AU2021253128A AU2021253128A1 (en) 2020-04-07 2021-04-06 Crystalline forms of a TYK2 inhibitor
EP21717041.4A EP4132649A1 (en) 2020-04-07 2021-04-06 Crystalline forms of a tyk2 inhibitor
CN202180025999.3A CN115515683B (zh) 2020-04-07 2021-04-06 Tyk2抑制剂的晶型
CA3167172A CA3167172A1 (en) 2020-04-07 2021-04-06 Crystalline forms of a tyk2 inhibitor
US17/905,183 US12545652B2 (en) 2020-04-07 2021-04-06 Crystalline forms of a TYK2 inhibitor
JP2022559959A JP7660135B2 (ja) 2020-04-07 2021-04-06 Ｔｙｋ２阻害剤の結晶形態

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2005114.0A GB202005114D0 (en) 2020-04-07 2020-04-07 Crystalline Forms of a Pharmaceutical Compound

Publications (1)

Publication Number Publication Date
GB202005114D0 true GB202005114D0 (en) 2020-05-20

Family

ID=70768933

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2005114.0A Ceased GB202005114D0 (en) 2020-04-07 2020-04-07 Crystalline Forms of a Pharmaceutical Compound

Country Status (12)

Country Link
US (1) US12545652B2 (https=)
EP (1) EP4132649A1 (https=)
JP (1) JP7660135B2 (https=)
KR (1) KR20220164751A (https=)
CN (1) CN115515683B (https=)
AU (1) AU2021253128A1 (https=)
BR (1) BR112022016359A2 (https=)
CA (1) CA3167172A1 (https=)
GB (1) GB202005114D0 (https=)
IL (1) IL296989A (https=)
MX (1) MX2022011593A (https=)
WO (1) WO2021204762A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
WO2023183910A1 (en) * 2022-03-25 2023-09-28 Nimbus Lakshmi, Inc. Solid forms of tyk2 inhibitors and methods of use

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794096A (fr) 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
GB1497536A (en) 1973-12-17 1978-01-12 Lilly Industries Ltd 2-acylaminooxazoles methods for their preparation and their use
JPH0753716B2 (ja) 1986-07-02 1995-06-07 吉富製薬株式会社 イミダゾ−ルカルボキサミド誘導体
DE19653355A1 (de) 1996-12-20 1998-06-25 Dresden Arzneimittel Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
IL153246A0 (en) 2000-06-28 2003-07-06 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
DE60128731T2 (de) 2000-10-30 2008-02-07 Janssen Pharmaceutica N.V. Tripeptidylpeptidase-hemmer
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
EP1684750B1 (en) 2003-10-23 2010-04-28 AB Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
JP5222561B2 (ja) 2005-10-07 2013-06-26 キッセイ薬品工業株式会社 含窒素芳香族複素環化合物およびそれを含有する医薬組成物
ES2352320T3 (es) 2006-05-12 2011-02-17 Ab Science Nuevo procedimiento para la síntesis de compuestos de 2-aminoxazol.
WO2008024980A2 (en) 2006-08-24 2008-02-28 Serenex, Inc. Pyrrole, thiophene, furan, imidazole, oxazole, and thiazole derivatives
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
JP5478488B2 (ja) 2007-06-20 2014-04-23 メルク・シャープ・アンド・ドーム・コーポレーション Ｊａｎｕｓキナーゼの阻害剤
EP2278969B1 (en) 2008-04-21 2013-02-13 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
EP2299816B1 (en) 2008-06-18 2013-11-13 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
US8420695B2 (en) 2008-07-09 2013-04-16 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US20130096104A1 (en) 2010-03-17 2013-04-18 Genentech, Inc. Imidazopyridine compounds, compositions and methods of use
EP2588105A1 (en) 2010-07-01 2013-05-08 Cellzome Limited Triazolopyridines as tyk2 inhibitors
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN103987713A (zh) 2011-10-12 2014-08-13 阵列生物制药公司 5,7-取代的咪唑并[1,2-c]嘧啶
EP3040336B1 (en) 2012-03-02 2020-04-08 Sareum Limited Compounds for use in treating tyk2 kinase mediated conditions
KR101202026B1 (ko) 2012-07-03 2012-11-16 민호현 황토 석부작 제조 방법
LT3495358T (lt) 2012-11-08 2022-05-25 Bristol-Myers Squibb Company Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai
MX369974B (es) * 2013-09-03 2019-11-27 Sareum Ltd Compuestos farmaceuticos.
NO2721710T3 (https=) 2014-08-21 2018-03-31
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
GB201816369D0 (en) * 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
US20230159473A1 (en) 2023-05-25
BR112022016359A2 (pt) 2022-10-04
MX2022011593A (es) 2022-10-18
WO2021204762A1 (en) 2021-10-14
JP2023521631A (ja) 2023-05-25
US12545652B2 (en) 2026-02-10
CA3167172A1 (en) 2021-10-14
JP7660135B2 (ja) 2025-04-10
IL296989A (en) 2022-12-01
EP4132649A1 (en) 2023-02-15
CN115515683B (zh) 2024-10-25
KR20220164751A (ko) 2022-12-13
AU2021253128A1 (en) 2022-08-25
CN115515683A (zh) 2022-12-23

Similar Documents

Publication Publication Date Title
SG11202107225SA (en) Crystalline form of a cdk inhibitor
PT3972960T (pt) Formas cristalinas de um inibidor de btk
IL316075A (en) Crystalline form of lenifranor
DK4114826T3 (da) Krystallinske former af en farmaceutisk forbindelse
AU2021400317A9 (en) Solid forms of a compound
IL289929A (en) Crystal forms of cd73 inhibitor
IL321053A (en) Crystalline forms of HER2 inhibitor
EP3923948A4 (en) CRYSTALLINE SHAPES OF A JAK2 INHIBITOR
GB202102360D0 (en) Crystalline compound
IL288547A (en) Salts of non-hygroscopic crystalline pyrazole compound, pharmaceutical preparations thereof and use thereof
GB202005114D0 (en) Crystalline Forms of a Pharmaceutical Compound
IL281168A (en) Crystal forms of the quinazole compound and its hydrochloride salts
GB2593902B (en) Salt of a pharmaceutical compound
IL304683A (en) Crystalline form of a piperazinyl-thiazole derivative
IL285427A (en) Crystal forms of jak2 inhibitor
EP3927707A4 (en) SOLID POLYMORPHS OF AN FLNA BINDING COMPOUND AND ITS HYDROCHLORIDE SALTS
GB202301180D0 (en) Salt of a pharmaceutical compound
IL284564A (en) Polymorphic forms of a modified quinoline-type bridged piperidine compound
GB202213819D0 (en) Pharmaceutical compound
IL292206A (en) The salts of a compound and its crystalline forms
HK40104193A (en) Crystalline form of a piperazinyl-thiazole derivative
HK40099801A (en) Solid forms of a compound
GB202217726D0 (en) Crystalline compound
PL4347565T3 (pl) Otrzymywanie związku inhibitora chk1
HK40086278A (en) Crystalline forms of a tyk2 inhibitor

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)